C-OPTIMISE: Certolizumab Pegol Therapy Withdrawal in Patients With axSpA Associated With Increased Disease Activity in Patients Without Flares

June 2-5, 2021; Virtual
Even without flare, withdrawal of CZP associated with increased ASDAS, CRP, BASDAI, and fecal calprotectin.
Format: Microsoft PowerPoint (.ppt)
File Size: 327 KB
Released: August 3, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Related Content

Clinical Care Options (CCO) presents expert faculty discussing options for the treatment and care of patients with rheumatic disease during flu season.

Cassandra Calabrese, DO Released: December 2, 2022

Nurse Practitioners: 0.5 AANP contact hours Released: August 5, 2022 Expired: August 31, 2023

Slides featuring expert discussion of managing the physical and emotional elements of pediatric psoriasis

Victoria Garcia-Albea, NP, DCNP Robert Sidbury, MD, MPH Released: February 8, 2022

Interactive video roundtable featuring expert discussion of managing the physical and emotional elements of pediatric psoriasis.

Victoria Garcia-Albea, NP, DCNP Robert Sidbury, MD, MPH Physicians: maximum of 0.75 AMA PRA Category 1 Credits Nurse Practitioners: 0.75 NAPNAP CE contact hour, 0.25 pharmacology content Released: February 7, 2022 Expired: February 6, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings